PRISCILLA LEIBEL: Open Payments
NPI 1730652439 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,522 in 158 payments from 20 companies in 2025. Trend: 2023 $3,222 · 2024 $3,357 · 2025 $3,522
Food & beverage: $3,522
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $440 |
| Janssen Biotech, Inc. | 17 | $411 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $393 |
| Madrigal Pharmaceuticals | 10 | $371 |
| Phathom Pharmaceuticals, Inc. | 11 | $362 |
| GENZYME CORPORATION | 8 | $226 |
| Lilly USA, LLC | 11 | $225 |
| Celltrion USA Inc. | 9 | $198 |
| Regeneron Healthcare Solutions, Inc. | 5 | $169 |
| QOL Medical, LLC | 5 | $116 |
Products named: TREMFYA, DUPIXENT, XIFAXAN, REZDIFFRA, VOQUEZNA, RINVOQ, OMVOH, VEGZELMA.
Industry payments across TX — which companies pay providers there.
